A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

February 15, 2018

Type of Cancer

Hematological Malignancies

Sponsor

Novartis Pharmaceuticals

Protocol Number

CSEG101A2202

To Learn More Call

(201)-510-0950